

Applicant: Donovan  
Serial No.: 09/489,667  
Filed: January 19, 2000  
Page 2 of 8

The Examiner has indicated during a telephone conversation on January 8, 2002 with Applicant's representative, Dr. Greg S. Holtrigel, that the CRF of the sequence listing filed September 11, 2001 has been entered and need not be resubmitted. Therefore, Applicant encloses an identical copy of the paper Sequence Listing that was filed September 11, 2001. Also, Applicant encloses a copy of the Declaration stating that the computer readable form and paper copy are identical and include no new matter. The paper copy submitted herewith is identical to the CRF submitted September 11, 2001.

**In the Claims:**

Please cancel claims 66-68 without prejudice. Applicant reserves the right to pursue the subject matter of this claim in a related application at Applicant's discretion.

Please replace claims 69-80 with the following claims:

69. (Amended) An agent for treating pain comprising a modified clostridial neurotoxin, wherein the clostridial neurotoxin has been modified by covalently coupling substance P to the clostridial neurotoxin so that the clostridial neurotoxin no longer binds to neurotoxin receptors at a neuromuscular junction with the same affinity as a native clostridial neurotoxin.
70. (Amended) The agent of claim 69 wherein the clostridial neurotoxin is produced by an organism selected from the group consisting of Clostridial beratti, Clostridial butyricum, Clostridial botulinum and Clostridial tetani.
71. (Amended) The agent of claim 69 wherein the clostridial neurotoxin is a botulinum toxin selected from the group consisting of serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

Applicant: Donovan  
Serial No.: 09/489,667  
Filed: January 19, 2000  
Page 3 of 8

72. (Amended) The agent of claim 69 wherein the clostridial neurotoxin is botulinum toxin serotype A.
73. (Amended) The agent of claim 69 wherein the clostridial neurotoxin comprises an H<sub>N</sub> and an L chain.
74. The agent of claim 73 wherein the H<sub>N</sub> is produced by an organism selected from the group consisting of Clostridial beratti, Clostridial butyricum, Clostridial botulinum and Clostridial tetani.
75. The agent of claim 73 wherein the L chain is produced by an organism selected from the group consisting of Clostridial beratti, Clostridial butyricum, Clostridial botulinum, and Clostridial tetani.
76. The agent of claim 73 wherein the H<sub>N</sub> is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.
77. (Amended) An agent for treating pain comprising a botulinum toxin, without an H<sub>c</sub> that binds to receptors at the neuromuscular junction with the same affinity as native botulinum toxin, covalently coupled to substance P.
78. (Amended) An agent for treating pain comprising a botulinum toxin serotype A, without a functional H<sub>c</sub> domain, covalently coupled to substance P.
79. An agent for treating pain comprising a botulinum toxin covalently coupled to substance P, wherein an H<sub>c</sub> of the toxin has been removed.